CY1105424T1 - Συζυγη ανθρωπινης ρεδουκτασης 2 κινονης για adept και gdept - Google Patents
Συζυγη ανθρωπινης ρεδουκτασης 2 κινονης για adept και gdeptInfo
- Publication number
- CY1105424T1 CY1105424T1 CY20061100305T CY061100305T CY1105424T1 CY 1105424 T1 CY1105424 T1 CY 1105424T1 CY 20061100305 T CY20061100305 T CY 20061100305T CY 061100305 T CY061100305 T CY 061100305T CY 1105424 T1 CY1105424 T1 CY 1105424T1
- Authority
- CY
- Cyprus
- Prior art keywords
- nqo2
- prodrug
- fragment
- fusion
- variant
- Prior art date
Links
- 238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 title 1
- 238000010914 gene-directed enzyme pro-drug therapy Methods 0.000 title 1
- 102100022353 Ribosyldihydronicotinamide dehydrogenase [quinone] Human genes 0.000 abstract 10
- 102000040430 polynucleotide Human genes 0.000 abstract 4
- 108091033319 polynucleotide Proteins 0.000 abstract 4
- 239000002157 polynucleotide Substances 0.000 abstract 4
- 229940002612 prodrug Drugs 0.000 abstract 4
- 239000000651 prodrug Substances 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 3
- 230000004927 fusion Effects 0.000 abstract 3
- 101710131813 Ribosyldihydronicotinamide dehydrogenase [quinone] Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 235000020956 nicotinamide riboside Nutrition 0.000 abstract 1
- 239000011618 nicotinamide riboside Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Nanotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Electrotherapy Devices (AREA)
- Percussion Or Vibration Massage (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9712370.7A GB9712370D0 (en) | 1997-06-14 | 1997-06-14 | Therapeutic systems |
| PCT/GB1998/001731 WO1998057662A2 (en) | 1997-06-14 | 1998-06-15 | Therapeutic systems |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1105424T1 true CY1105424T1 (el) | 2010-04-28 |
Family
ID=10814135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061100305T CY1105424T1 (el) | 1997-06-14 | 2006-03-07 | Συζυγη ανθρωπινης ρεδουκτασης 2 κινονης για adept και gdept |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US6867231B1 (enExample) |
| EP (2) | EP1468698A3 (enExample) |
| JP (1) | JP4272263B2 (enExample) |
| AT (1) | ATE311905T1 (enExample) |
| CA (1) | CA2292608A1 (enExample) |
| CY (1) | CY1105424T1 (enExample) |
| DE (1) | DE69832702T2 (enExample) |
| DK (1) | DK0988059T3 (enExample) |
| ES (1) | ES2257810T3 (enExample) |
| GB (2) | GB9712370D0 (enExample) |
| HK (1) | HK1041824B (enExample) |
| WO (1) | WO1998057662A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9712370D0 (en) * | 1997-06-14 | 1997-08-13 | Aepact Ltd | Therapeutic systems |
| GB9903019D0 (en) * | 1999-02-10 | 1999-03-31 | Microbiological Res Authority | Nitroreductase enzymes |
| EP1210358A4 (en) * | 1999-08-13 | 2005-01-05 | Univ Brandeis | PROOF OF NUCLEIC ACIDS |
| CN1315529A (zh) * | 2000-03-29 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人醌蛋白还原酶9和编码这种多肽的多核苷酸 |
| WO2003025128A2 (en) * | 2001-09-14 | 2003-03-27 | Duke University | Quinone reductase 2 and aldehyde dehydrogenase as therapeutic targets |
| GB0328314D0 (en) * | 2003-12-05 | 2004-01-07 | Univ Bath | Therapeutics |
| EP1723227A4 (en) * | 2004-02-10 | 2007-09-19 | Dartmouth College | NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE |
| US8114626B2 (en) * | 2004-02-10 | 2012-02-14 | Trustees Of Dartmouth College | Yeast strain and method for using the same to produce nicotinamide riboside |
| US7910593B2 (en) | 2004-04-09 | 2011-03-22 | Chugai Seiyaku Kabushiki Kaisha | Water-soluble prodrugs |
| EP2805719A1 (en) * | 2005-03-30 | 2014-11-26 | Glaxosmithkline LLC | Nicotinamide riboside and analogues thereof |
| US20070014833A1 (en) * | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| US20060292099A1 (en) * | 2005-05-25 | 2006-12-28 | Michael Milburn | Treatment of eye disorders with sirtuin modulators |
| TW200744603A (en) | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
| GB0517957D0 (en) | 2005-09-03 | 2005-10-12 | Morvus Technology Ltd | Method of combating infection |
| GB0526552D0 (en) | 2005-12-29 | 2006-02-08 | Morvus Technology Ltd | New use |
| GB2442202A (en) | 2006-09-30 | 2008-04-02 | Morvus Technology Ltd | Vermin poison |
| CA2956163C (en) | 2014-07-24 | 2023-01-10 | W.R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
| ES2963057T3 (es) | 2015-03-09 | 2024-03-25 | Grace W R & Co | Forma cristalina de ribósido de nicotinamida |
| NZ735411A (en) * | 2015-03-16 | 2021-07-30 | Chromadex Inc | Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof |
| WO2017011788A1 (en) * | 2015-07-15 | 2017-01-19 | Cornell University | Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives |
| NZ803738A (en) | 2016-11-11 | 2024-05-31 | Chromadex Inc | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof |
| EP3554285A4 (en) | 2016-11-29 | 2021-01-20 | University of Iowa Research Foundation | USE OF NAD PRECURSORS TO IMPROVE THE HEALTH OF MOTHER AND / OR OFFspring |
| US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
| EP3727400A4 (en) | 2017-12-22 | 2021-10-20 | Elysium Health, Inc. | CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US440859A (en) * | 1890-11-18 | Wire-rope machine | ||
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| JPS5460386A (en) * | 1977-10-20 | 1979-05-15 | Fuji Photo Film Co Ltd | Photopolymerizable composition |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| YU44186B (en) | 1978-12-22 | 1990-04-30 | Biogen Nv | Process for obtaining recombinant dnk molecules |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US5087618A (en) * | 1982-05-18 | 1992-02-11 | University Of Florida | Redox carriers for brain-specific drug delivery |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| JPS60184252A (ja) * | 1984-03-02 | 1985-09-19 | Canon Inc | 電子写真感光体 |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| GB8615701D0 (en) | 1986-06-27 | 1986-08-06 | Delta Biotechnology Ltd | Stable gene integration vector |
| GB8620926D0 (en) | 1986-08-29 | 1986-10-08 | Delta Biotechnology Ltd | Yeast promoter |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| NZ225599A (en) | 1987-08-04 | 1991-09-25 | Bristol Myers Co | Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells |
| US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| GB8809616D0 (en) | 1988-04-22 | 1988-05-25 | Cancer Res Campaign Tech | Further improvements relating to drug delivery systems |
| ATE135045T1 (de) | 1988-07-23 | 1996-03-15 | Delta Biotechnology Ltd | Sekretorische leader-sequenzen |
| GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
| GB8929097D0 (en) | 1989-12-22 | 1990-02-28 | Imp Cancer Res Tech | Mucin nucleotides |
| GB9001641D0 (en) | 1990-01-24 | 1990-03-21 | Imp Cancer Res Tech | Compounds |
| JP4115514B2 (ja) | 1991-10-23 | 2008-07-09 | キャンサー・リサーチ・キヤンペーン・テクノロジー・リミテツド | Ｃｂ １９５４およびその類似体を細胞障害性の形態に還元するための細菌のニトロリダクターゼ |
| GB9200417D0 (en) | 1992-01-09 | 1992-02-26 | Bagshawe Kenneth D | Cytotoxic drug therapy |
| GB9200415D0 (en) | 1992-01-09 | 1992-02-26 | Bagshawe Kenneth D | Inactivation of cytotoxic drugs |
| GB9323008D0 (en) * | 1993-11-05 | 1994-01-05 | Connors Thomas | Improvements relating to cancer therapy |
| GB9516943D0 (en) * | 1995-08-18 | 1995-10-18 | Cancer Soc Auckland Div Nz Inc | Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs |
| GB9524942D0 (en) | 1995-12-06 | 1996-02-07 | Aepact Ltd | Drug therapy |
| EP0869818A1 (en) | 1995-12-29 | 1998-10-14 | AEPACT Limited | Cytotoxic agents |
| WO1998022577A1 (en) | 1996-11-15 | 1998-05-28 | Maria Grazia Masucci | Fusion proteins having increased half-lives |
| GB9624993D0 (en) | 1996-11-30 | 1997-01-15 | Aepact Ltd | Tumour therapy |
| GB9712370D0 (en) * | 1997-06-14 | 1997-08-13 | Aepact Ltd | Therapeutic systems |
-
1997
- 1997-06-14 GB GBGB9712370.7A patent/GB9712370D0/en active Pending
-
1998
- 1998-06-15 EP EP04076964A patent/EP1468698A3/en not_active Withdrawn
- 1998-06-15 JP JP50395399A patent/JP4272263B2/ja not_active Expired - Fee Related
- 1998-06-15 DK DK98929555T patent/DK0988059T3/da active
- 1998-06-15 EP EP98929555A patent/EP0988059B8/en not_active Expired - Lifetime
- 1998-06-15 GB GB9928237A patent/GB2341605B/en not_active Expired - Fee Related
- 1998-06-15 CA CA002292608A patent/CA2292608A1/en not_active Abandoned
- 1998-06-15 US US09/445,865 patent/US6867231B1/en not_active Expired - Fee Related
- 1998-06-15 AT AT98929555T patent/ATE311905T1/de not_active IP Right Cessation
- 1998-06-15 ES ES98929555T patent/ES2257810T3/es not_active Expired - Lifetime
- 1998-06-15 DE DE69832702T patent/DE69832702T2/de not_active Expired - Fee Related
- 1998-06-15 WO PCT/GB1998/001731 patent/WO1998057662A2/en not_active Ceased
-
2000
- 2000-04-13 HK HK02103701.2A patent/HK1041824B/zh not_active IP Right Cessation
-
2002
- 2002-03-13 US US10/099,830 patent/US7138122B2/en not_active Expired - Fee Related
-
2006
- 2006-03-07 CY CY20061100305T patent/CY1105424T1/el unknown
- 2006-11-09 US US11/558,042 patent/US20070166296A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1468698A2 (en) | 2004-10-20 |
| WO1998057662A2 (en) | 1998-12-23 |
| JP4272263B2 (ja) | 2009-06-03 |
| WO1998057662A3 (en) | 1999-08-12 |
| DK0988059T3 (da) | 2006-01-23 |
| DE69832702T2 (de) | 2006-08-10 |
| GB9712370D0 (en) | 1997-08-13 |
| US20070166296A1 (en) | 2007-07-19 |
| JP2002511754A (ja) | 2002-04-16 |
| EP0988059A2 (en) | 2000-03-29 |
| US6867231B1 (en) | 2005-03-15 |
| EP0988059B8 (en) | 2006-03-01 |
| HK1023069A1 (en) | 2000-09-01 |
| EP1468698A3 (en) | 2005-03-23 |
| US7138122B2 (en) | 2006-11-21 |
| GB2341605B (en) | 2002-02-20 |
| HK1041824A1 (en) | 2002-07-26 |
| GB2341605A (en) | 2000-03-22 |
| ATE311905T1 (de) | 2005-12-15 |
| GB9928237D0 (en) | 2000-01-26 |
| US20030086933A1 (en) | 2003-05-08 |
| GB2341605A8 (en) | 2000-03-28 |
| EP0988059B1 (en) | 2005-12-07 |
| DE69832702D1 (de) | 2006-01-12 |
| HK1041824B (zh) | 2002-11-15 |
| ES2257810T3 (es) | 2006-08-01 |
| CA2292608A1 (en) | 1998-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2341605A (en) | Therapeutic systems | |
| ATE93236T1 (de) | Acylatiertes uridin und cytidin und deren verwendungen. | |
| CY1106798T1 (el) | Ανθρωπινα μεσεγχυματικα βλαστοκυτταρα απο περιφερειακο αιμα | |
| TR199700574T1 (xx) | Molek�ler �aperon �retiminin haz�rlanmas� i�in yararl� hidroksilamin t�revleri ve bu t�revlerin haz�rlanmas�. | |
| HN1998000143A (es) | Tetrahidronaftalenos substituidos y compuestos analogos. | |
| SG81890A1 (en) | Compounds for treating a condition or disease in a human related to supranormal intracellular enzyme activity | |
| KR900701827A (ko) | 치료용 펩타이드 | |
| ES2095772T3 (es) | Utilizacion de derivados de rifamicina para producir un medicamento destinado al tratamiento de la toxoplasmosis. | |
| DK0527757T3 (da) | Sammensætning og fremgangsmåde til behandling af akne vulgaris og forsinkelse af ældning | |
| NO20000576L (no) | Blanding og fremgangsmåte for regulering av celleproliferasjon og celledød | |
| DK0817646T3 (da) | Fremgangsmåder til behandling af inflammation og præparater derfor | |
| PT1212428E (pt) | Redireccionamento da expressao do gene gama 34.5 de herpes atraves de um promotor especifico de celulas e/ou especifico de tumores | |
| ES2043610T3 (es) | Procedimiento para la produccion de un polipeptido hibrido del tipo activador de plasminogeno. | |
| BR9916460A (pt) | Produção de ácido ascórbico usando levedura | |
| NL350033I2 (nl) | Gefuseerde middelen voor biologische controle | |
| ATE222914T1 (de) | Diester-derivate von acyclovir | |
| EA199801007A1 (ru) | Способ биосинтеза, позволяющий получать кобаламины | |
| NO980275D0 (no) | Dobbelt virusinaktivert humant blodplasma, blodplasmaderivater fremstilt derav og fremgangsmåte for deres fremstilling | |
| ES2066422T3 (es) | Expresion de un arn multigenes con actividad de autoempalme. | |
| ATE499115T1 (de) | Antikörper verwiesene enzymprodrugtherapie mit glukuronidase | |
| RU2000106057A (ru) | Применение никотинамидадениндинуклеотида и его аналогов для лечения злокачественных и инфекционных заболеваний | |
| AR009470A1 (es) | COMPOSICIoN FARMACÉUTICA QUE CONTIENE CEPAS BACTERIANAS Y UTILES EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON O CAUSADAS POR ALTERACIONES EN EL METABOLISMO DE LOS ÁCIDOS BILIARES, Y USO DE LAS MISMAS. | |
| Yoo et al. | Identification of Ser-543 as the major regulatory phosphorylation site in spinach leaf nitrate reductase | |
| GT199300023A (es) | Derivados de aminoacidos | |
| GT199200002A (es) | Derivados de aminoacidos |